i feel like some new drug by 2020, lets c.
Press release from Abivax:
* Post-treatment monitoring of patients will be continued as per protocol in order to provide additional insight on clinical trial outcomes and secondary endpoints
* Future development of ABX203 under review, including addition of an adjuvant, new administration schedules and therapeutic combinations
It is 5.5 log reduction in hbvdna, not HBsAg. Since patients are on Entecavir, these types of reduction in hbvdna are not unusual.
I feel the only leading HBV drug on pipeline is ARWR( Arc-520).
This is a very comprehensive and timely article about HBV drugs in development. ABX203 was not mentioned, even though one clinical trial is still on-going. Most of the others are well-known to us all - very hard to get excited about.
It would be interesting to know more about the "undisclosed mechanism" of the Johnson& Johnson and Roach's drugs. It is hard to tell whether they do not want to disclose because they are just like the others or represent some new approaches.
Hepatitis B therapy pipeline
Project / Company / Pharmacology / Trial ID / Data due?
Phase II
GS-9620 Giled Sciences TLR7 agonist NCT02166047 & NCT02579382 Imminent & Dec 2016
GS-4774 Sciences/Globeimmune Therapeutic vaccine NCT02174276 Imminent
Myrcludex B Viral entry inhibitor NCT02637999 Imminent
REP 2139 Replicor HBsAg release inhibitor
NCT02726789 Sep 2016
ARC-520 Arrowhead Pharmaceuticals RNAi therapeutic NCT02604199 and 4 others Oct 2016
ARB-1467 Arbutus Biopharma RNAi therapeutic NCT02631096 Oct 2016
CMX157 Chimerix/Contravir NNRTI NCT02710604 Oct 2016
GC1102 Green Cross (Korea) Recombinant hep B immunoglobulin NCT02569372 May 2017
RO6864018 Roche Not disclosed NCT02391805 Sep 2017
SB 9200 Spring Bank Pharmaceuticals RIG-I & NOD2 activator NCT02751996 Dec 2017
REP 2165 Replicor HBsAg release inhibitor NCT02565719 Sep 2018
Phase I
NVR 3-778 Johnson & Johnson Capsid inhibitor NCT02401737 Imminent
JNJ-56136379 Johnson & Johnson Not disclosed NCT02662712 Nov 2016
IONIS-HBV-LRx GlaxoSmithKline/Ionis Hepatitis B antisense NCT02647281 Nov 2016
HepTcell (FP-02.2) Altimmune Therapeutic vaccine NCT02496897 Feb 2017 RO7020322 Roche Not disclosed NCT02604355 Apr 2017
ARC-521 Arrowhead Pharmaceuticals ccc DNA-targeting RNAi NCT02797522 Jun 2017
TG1050 Transgene Therapeutic vaccine NCT02428400 Mar 2018
INO-1800/RG7944 Inovio Pharmaceuticals Therapeutic vaccine NCT02431312 Dec 2018
RG7834 Roche Not disclosed – (1st pt in Q4 2015)
AIC649 Aicuris Therapeutic vaccine – –
EYP001 Enyo Pharma Farnesoid X receptor agonist – –
GSK3228836 GlaxoSmithKline/Ionis Hepatitis B antisense – –
Source: EvaluatePharma and Clinicaltrials.gov.
http://seekingalpha.com/article/4000028-hepatitis-b-developers-try-repeat-gileads-hep-c-trick
more readable form here :)
http://www.hepb.org/treatment-and-management/drug-watch/